附件 99.1

iBio報告財務結果 第一季度202年第一季度5 財務結果

·  非人靈長類動物研究中進行中的Advanced myostatin項目

2024年11月12日，加利福尼亞聖地亞哥（GLOBE NEWSWIRE）——iBio，Inc.（NYSEA: IBIO）今天報告了截止於2024年9月30日的第一季度財務業績，並就其進展提供了企業更新。

​

在我們的財政第一季度，我們加強了與AstralBio的合作，製造和給非人靈長類動物注射了一種具有肌肉消耗和肥胖治療潛力的首要分子 體內首席執行官兼首席科學官馬丁·布倫納博士表示：「在我們的財政第一季度，我們加強了與AstralBio的合作，通過聘請經驗豐富的業務發展高管克里斯蒂·薩諾，進一步推進了肌肉消耗和肥胖等額外目標的早期研究。 這一舉措對我們努力爲抗體發展合作伙伴提供關鍵支持至關重要。 我們對我們的快速進展感到滿意，並期待在未來幾個月分享數據和進展，因爲我們致力於將我們的藥物管線推進到心腦血管疾病和肥胖的臨床階段。」

​

2025財政第一季度及最新企業動態更新：

​

​

2025財年第一季度財務業績：

​

​

​

​

關於iBio，Inc。

iBio是一家以人工智能驅動的創新者，利用計算生物學和三維建模技術開發下一代生物製藥產品，有望發現難以靶向的癌症和其他疾病的新抗體治療方法。iBio的使命是減少藥物失敗率，縮短藥物開發時間，並在最有前景的目標上開拓新領域。欲了解更多信息，請訪問www.ibioinc.com.

​

Safe Harbor聲明

Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 「forward-looking statements.」 These statements include statements regarding the Company’s ability to build its pipeline in cardiometabolic diseases and obesity; the hiring of a business development executive by the Company resulting in critically enabling new partners in antibody development for challenging targets; the success of the Company’s development of next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes in prospectively enabling the discovery of new antibody treatments for hard to target cancers and other diseases; having initial data in early 2025 from non-the cGMP in vivo non-human primates (NHP) study; continuing to advance toward iBio’s goal of decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets, and iBio’s ability to build a pipeline in obesity and other cardiometabolic diseases. The words 「anticipate,」 「believe,」 「continue,」 「could,」 「estimate,」 「expect,」 「intend,」 「may,」 「plan,」 「potential,」 「predict,」 「project,」 「should,」 「target,」 「will,」 「would」 and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to build its pipeline in cardiometabolic diseases and obesity; the ability to complete the non-cGMP in vivo non-human primates (NHP) study, the success of the Company’s development of next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes in prospectively enabling the discovery of new antibody treatments for hard to target cancers and other diseases; iBio’s ability to advance its goal of decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets, and the ability to build a pipeline in obesity and other cardiometabolic diseases, the ability to finance when needed and the risk factors described in the Company’s Annual Report on Form 10-k for the year ended June 30, 2024, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-k. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc.  specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

​

​

聯繫人：

iBio，Inc。
投資者關係
ir@ibioinc.com

Susan Thomas
iBio，Inc.
媒體關係
susan.thomas@ibioinc.com